A study published on July 23 by researchers at Memorial Sloan Kettering Cancer Center reports that inhibiting a signaling molecule called MEK could potentially limit T cell exhaustion and improve the effectiveness of cancer immunotherapy. The findings, based on animal studies and published in Immunity, address a longstanding challenge with checkpoint inhibitor drugs: T cells often become exhausted before eliminating tumors, reducing the impact of treatment.
Santosha Vardhana, MD, PhD, a physician-scientist at Memorial Sloan Kettering Cancer Center who treats lymphoma patients, said, "A tragic part of T cell exhaustion is that the immunotherapy seems to be working for patients, and then it fades. Many of them experience a brief wisp of promise only to have it taken away."
The research identified that continuous exposure to tumor antigens overtaxes mitochondria in T cells. This metabolic strain leads to an imbalance between energy supply and demand when producing cytotoxic proteins needed for attacking cancer cells. Tanmana Mitra, PhD, first author and student in the Vardhana lab, said, "We realized T cell exhaustion isn't simply a loss of function - it reflects an imbalance between what these cells are being asked to do and the energy they have available." The team found that exhausted T cells were still highly metabolically active but spent much of their energy making proteins rather than sustaining attack.
Treating these cells with MEK inhibitors resulted in greater proliferation while using less energy overall. Dr. Mitra explained, "That paradox made us ask where all that energy was going, and we discovered that these cells were investing enormous resources into making proteins." By limiting MEK signaling, some T cells remained active longer under harsh tumor conditions.
However, researchers cautioned against universal application of this approach for all cancer patients. Andrea Schietinger, PhD from MSKCC previously found that entering an exhausted state can help preserve T cell survival by avoiding overstimulation and death. Dr. Vardhana described exhaustion as "more of an equilibrium state that lets the cells survive and keep going - almost like a 'safe mode' for T cells." He further explained how ATP acts as cellular currency; if too much is spent on protein production during attack mode without enough conservation through mechanisms like MEK inhibition or exhaustion programs, T cell function declines rapidly.
Dr. Vardhana concluded, "This study shows the importance of understanding core principles of T cell biology - what sets the balance between conservation of energy and strong, cancer-fighting activity... Once we know the answer to that, the therapeutic possibilities really start to fan out." Additional authors on this study include Jahan Rahman, Madeline Hwee, Yan-Ting Chen among others.
